Brain Tumor Drug Development Targeting Treg Cells

The brain tumor is a type of central nervous system disease that severely affects the survival time and quality of life of patients and is extremely difficult to treat. For a long time, the main reason for tumor formation has been the immunosuppressed state of the body. This is reflected both by a decrease in the number and function of lymphocytes throughout the body and by local tissue tumor cells that influence the distribution of immune cells through signaling pathways such as signal transduction and activator of transcription 3 (STAT3) and indoleamine ⁃2,3⁃dioxygenase 1 (IDO1), contributing to remodeling of the tumor microenvironment (TME).

Our Brain Tumor Drug Development Services for Treg Targets

Regulatory T cells (Tregs) are a group of specific CD4-positive lymphocytes that function to suppress excessive and uncontrolled immune responses. In TME, Tregs are primarily responsible for suppressing the immune response of immune cells that attack tumors. Alfa Cytology focuses on the role of Tregs in immunosuppression. We can provide drug development services for clients in the field of brain tumor research to target Treg to stimulate the body's immune activity against brain tumors and kill tumor cells.

Our available targets

• CCR8. CCR8 is a member of the chemokine receptor family and is a G protein-coupled receptor.CCR8 is specifically expressed on tumor-infiltrating regulatory T cells (Treg). Its main role is to participate in the recruitment of Treg and Th2 cells to sites of inflammation and tumors.
• FoxP3. The main targets of Treg cells include CD25 and FoxP3. Among them, CD25 is widely expressed in humans, making FoxP3 the preferred target for Treg cells.
• PDL1 inhibitors. In addition to targeting Treg cells, other therapies that have the potential to reduce the number of Treg cells also have a significant impact on the prognosis of brain tumor patients. Programmed cell death protein ligand 1 (PDL1) maintains and promotes Treg cell proliferation, whereas PDL1 inhibitors inhibit Treg cell proliferation, which is closely related to patient survival. Therefore, PDL1 inhibitors targeting and regulating Treg cells have potential clinical value for the treatment of brain tumors.

Drug development processes

Taking the CCR8 target as an example, we can provide drug development services for CCR8 targets, mainly through monoclonal antibodies targeting CCR8 and small molecule antagonists targeting CCR8. For this important new immune target in brain tumors, we have also developed a relevant drug target cell screening model for the binding capacity and activity of large and small molecule drugs targeting CCR8.

We target CCR8 to enhance anti-brain tumor immunity by depleting brain tumor-infiltrating FOXp3⁺CCR8⁺ Treg cells or blocking the CCL1/CCR8 pathway. In addition, we have identified signaling molecules such as MHC-I, TGF-β, CCL2, PD-L1, Galectin-3, and STAT3 as potential targets for development. Because they all can promote Treg proliferation and inhibit effector T cells to participate in immune response while making tumor immune tolerant. This is one of the key directions of the next generation of brain tumor immune drugs that Alfa Cytology can now offer to its customers.

If you would like more information about PDL1 inhibitors or FoxP3 targets, please feel free to contact us. We look forward to helping you with your brain tumor drug development research.